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Summary
Radiomics describes the
extraction of multiple features
from medical images using
bioinformatic approaches to
provide additional information
to predict underlying tumor
biology and behavior. In rela-
tion to PET radiomics in ra-
diation therapy practice, early
data have reported radiomic
approaches to define tumor
volumes and predict radiation
toxicity and treatment
response. With many tech-
nical challenges remaining
and a need for standardization,
promise nevertheless exists
that PET radiomics will
contribute to personalized
medicine.
Purpose: Radiomics describes the extraction of multiple, otherwise invisible, features
from medical images that, with bioinformatic approaches, can be used to provide addi-
tional information that can predict underlying tumor biology and behavior.
Methods and Materials: Radiomic signatures can be used alone or with other patient-
specific data to improve tumor phenotyping, treatment response prediction, and prognosis,
noninvasively. The data describing 18F-fluorodeoxyglucose positron emission tomography
radiomics, often using texture or heterogeneity parameters, are increasing rapidly.
Results: In relation to radiation therapy practice, early data have reported the use of radio-
mic approaches to better define tumor volumes and predict radiation toxicity and treatment
response.
Conclusions: Although at an early stage of development, with many technical challenges
remaining and a need for standardization, promise nevertheless exists that PET radiomics
will contribute to personalized medicine, especially with the availability of increased
computing power and the development of machine-learning approaches for imaging. 
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Radiomics is a relatively new and evolving field in
medical imaging in which a large number of features are
extracted from medical images for analysis and interpre-
tation using bioinformatic approaches (1-4). It is assumed
that medical images contain more information than can be
appreciated by eye, and the underlying hypothesis on
which radiomics relies is that a relationship exists be-
tween such extracted image parameters and the tumor
molecular phenotype and/or genotype. The study of
radiomics is increasing and has become of greater aca-
demic interest since it has been recognized that genetic
heterogeneity exists within tumors and between metasta-
tic tumors in the same patient. Genotypic heterogeneity
contributes to the development of subpopulations of cells
with divergent biological behavior that are resistant to
treatment (5). At the biological level, it has been recog-
nized that heterogeneity of the tumor microenvironment
might be reflected in medical images, with respect to
cellular density, proliferation, angiogenesis, hypoxia,
receptor expression, necrosis, fibrosis, and inflammation
and that these factors can contribute to poor treatment re-
sponses and a more aggressive phenotype (6).
Therefore, interest is increasing in using radiomic sig-
natures to better determine the tumor phenotype. This
would allow for whole tumor segmentation or segmentation
of tumor subregions with different biological characteristics
that might contribute to treatment resistance and better
prediction and evaluation of the treatment response and
prognostication. Radiomic features can be used alone or
combined with other clinical or -omics data (eg, radio-
genomics) (7, 8).
In addition to standard or semantic features, such as
tumor dimension and volume or density/signal intensity on
computed tomography (CT) and magnetic resonance im-
aging (MRI) or the standardized uptake value (SUV) with
positron emission tomography (PET), many other param-
eters can be extracted from images. These relate to the
voxel-intensity volume histogram, spatial heterogeneity
between voxels of different intensities (texture analysis),
and tumor shape and surface outline, among other factors,
with the possibility of obtaining hundreds of features from
a single tumor (9-11).
The attractive characteristics of radiomics are the ability
to sample the whole tumor, negating the sampling error that
occurs with tissue biopsies and that the data can be
extracted noninvasively and using serial examinations.
Most radiomic features can be extracted from images that
have been acquired using standard image protocols and
thereby offer “free” additional information with only the
need for postprocessing. The disadvantages of the radio-
mics approach include that the extracted image parameters
relate to the relatively macroscopic scale and are therefore
unlikely to bear a direct relationship to underlying cellular
biology on a microscopic scale. Also, image parameters
derived from mathematical formulas might, in themselves,
not correspond to visual perception. For example, a pre-
clinical study of an orthotopic breast cancer model reported
that although some texture features are sensitive to the
spatial distribution of cells and others to the cellular den-
sity, they are not easily correlated to the histologic texture
or able to capture tumor cell heterogeneity (12).
Spatial resolution and, hence, voxel dimensions vary
between and within the different clinical imaging modal-
ities used in oncology from submillimeter with CT and
MRI to several millimeters with PET and single photon
emission CT. In addition to the larger voxels and resultant
coarser tumor sampling, PET and single photon emission
CT also show a further disadvantage with an inherently
lower signal/noise ratio. It is also unlikely that the features
extracted from a particular imaging modality will have the
same association with the underlying tumor characteristics
as those from another imaging modality. For example, CT
measures the tissue density inferred from absorption of X
rays but 18F-fluorodeoxyglucose (18F-FDG) PET measures
cellular glucose metabolism, and MRI measures differences
in proton density and relaxation properties. These differ-
ences pose both challenges and opportunities for hybrid
imaging (eg, PET/CT or PET/MRI), such that registered
images might provide incremental or complementary in-
formation compared with a single image data set. Although
most of the PET radiomics data have described 18F-FDG,
examples have also been reported of the use of radiomics to
predict the chemotherapy response in breast cancer using
18F-fluorothymidine (13) or for grading and prognosis in
high-grade gliomas using 18F-fluoroethyltyrosine (14).
Several technical challenges remain in the evaluation
and implementation of radiomic approaches in the clinic,
and we have discussed some of these further, together with
some of the early reported findings of PET radiomics that
relate to radiation therapy practice and might eventually
translate into the clinic.
Technical Aspects
Many of the additional parameters used in PET radiomics
relate to intratumoral heterogeneity (15-17), although other
features that relate to shape or other metrics have also been
described (18, 19). In the use of machine-learning algo-
rithms, such as with convolutional neural networks, the
features that combine to provide the radiomic signature
might be unknown (20). However, knowledge of spatial
heterogeneity in tumors is of interest in its own right, in
addition to being a part of selecting radiomic signatures.
The most commonly used methods include statistical fea-
tures (first-, second-, high-order). However, other methods
include model-based features (eg, fractals) or transform-
based approaches, which convert the spatial information
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in an image into frequency (Fourier) information or scale
and frequency (wavelet) information (9, 21, 22).
First-order features represent global measurements of a
tumor that do not convey any spatial information. Stan-
dard parameters such as SUV, metabolic volume (MV),
and total lesion glycolysis (the product of the mean SUV
and MV) fall within this group. However, other features
that can be derived from a histogram of voxel intensity
frequencies describe global heterogeneity (eg, skewness
[asymmetry] and kurtosis [peakedness], describing the
shape of the histogram) and entropy and energy (also
named uniformity), describing the randomness and ho-
mogeneity of voxel values, respectively. Second- and
high-order statistical features contain information on
spatial relationships between the intensities of 2 voxels
and are derived from co-occurrence or difference matrices
to give local or regional measures of heterogeneity, often
called “texture analysis” (10). Also, run length and size
zone matrices give information on runs of voxels or
groups of similar voxels in a certain direction (23).
Commonly used second-order features include entropy,
energy, homogeneity, and contrast (which should not be
confused with first- or high-order features that bear the
same names), which measure the relationships between
pairs of voxels. High-order features include those derived
from neighborhood gray-tone difference matrices, such as
coarseness, contrast, busyness, and complexity, which
describe the relationships between a voxel and those in
neighboring planes. These features are thought to best
represent the human perception of heterogeneity or
texture within an image (11).
Many hundreds of features have been described and can
be extracted from a tumor volume of interest, whatever the
imaging modality, and this in itself can pose challenges to
avoid overfitting and being able to manage collinearity and,
hence, the redundancy of features. The more features tested
in a model, the more samples that are required. Thus, unless
a small number of features that have previously shown
predictive value and robustness are to be used in a
hypothesis-driven approach, the data from hundreds of
patients might be required to avoid false-positive associa-
tions. Large samples are especially required for machine-
learning methods in which hundreds or thousands of data
sets might be required to train the algorithm when no a
priori assumptions are available regarding the meaning or
strength of the individual features.
Although PET scans performed for clinical purposes can
be retrospectively postprocessed for feature extraction, this
can present a further challenge in mining larger shared data
sets because interinstitutional (or even intrainstitutional)
standardization of image acquisition with PET is likely to
be lacking. This results from the variabilities in scanner
hardware from different manufacturers, injected activity,
acquisition time after injection, acquisition time per bed
position, CT parameters used for attenuation correction of
the PET data, matrix size, and slice thickness. For example,
it has been shown that the calculated texture features can
vary depending on the time an 18F-FDG PET/CT scan is
acquired after injection (24) and are also dependent on the
voxel dimensions (25, 26).
An additional factor in PET scan acquisition that has
been shown to affect measurement of texture features is
respiratory motion, because PET acquisitions typically
require a few minutes for each bed position. Respiratory
gating produces different, but probably more accurate, re-
sults because blurring due to motion is minimized but is not
routine in clinical acquisitions (27, 28).
Good progress has been made in standardizing 18F-FDG
PET/CT protocols in oncologic imaging in the United
States and Europe (29, 30), and a number of recommen-
dations are available on how to develop new imaging bio-
markers (31-33). In particular, some recommendations on
how the current limitations on the use of texture analysis
should be addressed have recently been reported (17).
However, as yet, the field of PET radiomics is far from
standardized, making it difficult to pool data or perform
meta-analyses.
Other factors that can vary between institutions and
might influence measurement of texture features include
the reconstruction algorithm adopted and the presence of
postreconstruction smoothing, which is commonly applied
to clinical images. Some features, such as first-order en-
tropy, appear to be relatively robust with little variation
using different reconstruction parameters. However, 40 of
50 other features were reported to show >30% variation
when calculated after the use of 5 different reconstruction
parameters in a previous study (34).
The aspect of the radiomic workflow that probably
causes the most controversy is the choice of the segmen-
tation method to delineate a tumor, for which a compromise
is often required between accuracy and reproducibility. The
method varies between manually drawn regions of interest,
which are subject to the greatest inter- and intraobserver
variability, to automatic or semiautomatic methods, such as
using a fixed percentage threshold of the maximum SUV
(SUVmax), commonly 40%, to more sophisticated methods
such as fuzzy locally adaptive Bayesian (35). A fixed
threshold method can underestimate the true tumor volume
by ignoring areas of low activity but is highly reproducible.
In contrast, the fuzzy locally adaptive Bayesian method is
better suited for heterogeneous volumes with low resolution
and variable noise and contrast, such as is typical with PET,
and has been reported to be accurate and reproducible in
phantom and patient data (36, 37). Although necrotic tissue
without 18F-FDG uptake is a relatively common finding, it
remains unclear whether necrotic subregions should be
included when segmenting tumors for texture analysis. It
also remains unclear to what extent the precision or
predictive value of a radiomic signature will be influenced
by segmentation method, with variable results reported
(37-39).
Another technical factor that can have a substantial ef-
fect on the calculation of texture features is the requirement
for binning or quantization of the PET data, such that the
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original voxel intensity values are downsampled into a
variable number of bins (17, 39-41). Bins are commonly
equally divided into a set number (eg, 64 or 128), or the
data can be placed into a variable number of bins of a fixed
width (eg, 1 SUVunit). The latter method has been reported
to correlate better with visual perception (42). Although no
consensus has been reached for standardization for quan-
tization in PET, using 64 equally divided bins has been a
common approach (43). However, going forward, this is an
important factor that requires standardization, given the
large effect it can have on the measurement of texture
features.
PET has relatively large voxels compared with MRI and
CT, and the ability to accurately measure heterogeneity
features without bias or dependence on volume is therefore
more challenging. Using probability theory, Brooks et al.
(25) calculated that a volume of 45 cm3 is required to
adequately sample the tumor without significant bias on
18F-FDG PET images of cervical cancer from a scanner
with 0.4  0.4  0.4 cm3 voxels. They reported that
second-order entropy is dependent on the tumor volume but
is 5 times more sensitive to changes in volume below the
45 cm3 threshold than above it (25). Another study reported
that several texture features are highly correlated with the
volume, that the correlation varies among different features,
and the level of correlation significantly decreases with
larger volume tumors (26). For example, second-order en-
tropy showed high correlation in volumes of <10 cm3 but
much less at volumes >10 cm3, suggesting a much lower
minimum volume than 45 cm3 might be applicable. Rather
than texture features being a surrogate for volume, that
study showed in a subgroup of patients with nonesmall cell
lung cancer (NSCLC) that heterogeneity and volume were
independent prognostic factors and therefore complemen-
tary, especially in tumors >10 cm3 (26).
Although correlation between texture parameters and
volume has been recognized, correlation between other
radiomic parameters, including standard metrics such as
SUV, is also common (41). This might either be due to
similarities in the mathematical algorithm used to derive
the features, leading to redundancy, or because an under-
lying biological process exists that affects more than 1
feature that might then be complementary to each other. It
has been suggested that correlations between SUV and
texture features can be minimized by using 32 bins (41).
However, in addition to reporting correlations between
texture features and standard metrics (eg, SUV or MV),
using multivariable analyses or more robust statistical ap-
proaches with machine-learning techniques might be
required to better understand or offset the effects of
parameter correlation and redundancy (17, 44, 45).
An important factor in the decision of which texture
features to use in a study in which serial measurements are
required will depend on the repeatability or test-retest
performance. Several parameters derived from 18F-FDG
PET have been reported to be as repeatable as SUV (mean
percentage differencew5%), including several local (eg,
second-order entropy) and regional heterogeneity pa-
rameters describing variations in intensity and size of
regions of homogeneous activity in 1 study using
esophageal cancer 18F-FDG PET data (43). A further
study reported 63 of 105 radiomic features (intensity,
shape, and texture) with an intraclass correlation >0.9 in
NSCLC data (46). Few parameters are robust to all the
technical factors described, in particular, quantization
and reconstruction algorithm, with lesser or variable,
but measurable, effects from segmentation and smoothing
(34, 38-40, 43, 47, 48).
Reaching consensus or being able to provide recom-
mendations or guidelines from the existing radiomic and
texture analysis data is problematic. Few systematic re-
views or meta-analyses have been performed, resulting in
difficulties with the adoption of radiomics into multicenter
clinical trials and clinical practice. This is partly owing to
the methodologic heterogeneity between reported studies
and/or the lack of sufficient detail to replicate an analysis.
Also, relatively few prospective studies with large numbers
of patients that include training and (preferably external)
validation cohorts to limit overfitting for testing specific
image features or radiomic signatures have been reported.
One review reported only 13% of studies (mainly MRI)
adopted a prospective design, and 63% described training
sets or cross-validation (21).
Other weaknesses in some of the data relate to the sta-
tistical analysis (21, 49). For example, when large numbers
of image features are tested, a correction for multiple
testing should normally be considered to avoid false-
positive associations resulting from chance (eg, Holm-
Bonferroni [50] or Benjamini-Hochberg [51] corrections),
unless the study was purely observational or hypothesis
generating. When this correction has been applied retro-
spectively in a systematic review, a large number of fea-
tures in several studies were no longer statistically
significant; this occurred in up to 45% of reviewed papers
(21). Another potential factor that might increase the type 1
error rates unless a correction is applied is the use of
optimal cutoffs to divide the data into high- and low-risk
groups that maximize the statistical significance (48).
Radiomics and Texture Analysis in
Radiation Therapy
Interest is increasing in the use of radiomics in the radiation
therapy community such that the term “radio-oncomics”
has been proposed. Although most of the reported data have
been on CT and MRI, potential applications exist for
18F-FDG PET/CT in this field (52).
Testing the hypothesis that tumors and normal tissues
will show different textures, a pilot study aimed to identify
the texture features from 18F-FDG PET/CT scans of head
and neck squamous cell cancer that could improve the
differentiation between tumor and normal tissues to opti-
mize radiation therapy planning (53). Twenty-seven first-,
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second-, and high-order features and structural features
were extracted from the PET and CT images, and K nearest
neighbors and decision tree-based nearest neighbor classi-
fiers were used. It was shown that PET and CT coarseness,
contrast, and busyness had high discriminatory ability and
that abnormal tissue was less uniform on PET but more
uniform on CT. However, combining PET and CT features
gave the best tissue characterization. Taking this further to a
voxel-based approach, the same group tested an automated
segmentation method using texture analysis from 18F-FDG
PET/CT in head and neck cancer and showed high
concordance with radiation oncologist delineations (54).
Their findings argue that the method has the potential to
reduce interobserver variability and improve treatment
planning accuracy (54).
More commonly, texture analysis has been studied to
evaluate the ability to predict or measure the treatment
response. Heterogeneity on 18F-FDG PET usually infers a
poor prognosis and decreases with successful treatment
(55-57).
In patients with NSCLC receiving either conventional
radiation therapy or stereotactic body radiation therapy
(SBRT), a number of first-order features, calculated from
the intensity-volume histogram of 18F-FDG PET/CT, were
able to predict for local and locoregional control with a
model of combined PET and CT features providing better
predictors (58). High-order features, in particular, coarse-
ness, from 18F-FDG PET have also shown predictive and
prognostic capability in NSCLC patients who underwent
chemoradiation therapy (57). A retrospective study of 26
patients with stage 1 NSCLC tested standard metrics and
texture parameters in pretherapy (SBRT) 18F-FDG PET/CT
scans for the prediction of local control, progression-free,
and overall survival (59). Although most features showed
good interobserver reproducibility, only the texture feature
of high-intensity large area emphasis predicted for local
control (P Z .03) and SUVmax for progression-free sur-
vival (PZ .03), with no PET parameters found for overall
survival on univariate analysis. No correction was per-
formed for multiple testing. A larger study of 63 patients
with NSCLC who underwent SBRT tested standard metrics
and 13 texture features in 18F-FDG PET/CT for disease-
specific and overall survival (60). On multivariate anal-
ysis, only dissimilarity, a second-order feature derived from
co-occurrence matrices, was associated with disease-
specific and disease-free survival (hazard ratio 0.822,
P Z .037; hazard ratio 0.834, P < .01, respectively).
A number of studies using texture analysis to predict the
response to chemoradiation therapy in esophageal cancer have
been reported (55, 61-63). Tixier et al. (55) tested a range of
first-, second-, and high-order features from 18F-FDGPETin a
cohort of 41 patients who underwent definitive chemo-
radiation therapy for prediction of an eventual response
measured using CT Response Evaluation Criteria In Solid
Tumors on diagnostic CT scans. Although no global features
were predictive, several local second-order features (eg, en-
tropy; P Z .0006) and regional high-order features (eg,
coarseness; P Z .0002) showed significant differences be-
tween responders and nonresponders (55). In a different study
comparing pre- and post-therapy 18F-FDG PET/CT indeces
with the pathologic tumor response for the prediction of
response to neoadjuvant chemoradiation therapy, it was found
that a decline in themeanSUV,pretherapy skewness, andpost-
therapy homogeneity were predictive (61). The same group
then reported a support vector machine model that combined
conventional PET parameters with heterogeneity measures
and clinical parameters with perfect accuracy (area under the
curve [AUC] 1.0) and no misclassifications (62). A similar
study used least absolute shrinkage and selection operator
regularization and logistic regression analysis to construct a
model of histologic features, T stage, PET-derived long run
low gray level emphasis, and CT-derived run percentage from
a volume of interest incorporating the gross tumor volume
from a rigidly coregistered radiation therapy planning scan to
predict the pathologic response (AUC 0.78; after internal
validation, AUC 0.74), which performed better than the
SUVmax (AUC 0.58 and 0.54, respectively) (63).
The potential for PET or PET/CT radiomics has also
been studied for the prediction of radiation toxicity. Re-
ported data suggest that combining CT and 18F-FDG PET
features from the lung might be able to predict for radiation
pneumonitis in patients receiving radiation therapy for
esophageal cancer (64) or that second-order features from
18F-FDG PET might predict radiation lung injury after
SBRT for stage 1 NSCLC (65). Similarly, high levels of
parotid 18F-FDG uptake and the texture feature of long run
high gray level emphasis in patients with head and neck
cancer, when added to a reference model (radiation dose
and baseline xerostomia score), improved the prediction of
radiation-induced xerostomia (66).
Conclusions
Many challenges remain in the field of radiomics, not least,
the need for consensus, reproducibility, standardization,
and prospective validation in clinical trials (17, 67).
Although PET has the advantage of being able to sensi-
tively interrogate specific and varied abnormalities in tumor
biology, its poorer resolution and variable noise pose
additional technical limitations. Nevertheless, 18F-FDG
PET/CT radiomics, frequently performed as texture anal-
ysis, have shown early promise in moving toward a
personalized approach to radiation therapy and other
oncologic therapy. Moving forward, it would seem likely
that artificial intelligence and machine-learning methods
will play a larger part in strengthening radiomic research
and accelerating clinical translation.
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